Insider Selling: TransMedics Group (NASDAQ:TMDX) Director Sells 9,624 Shares of Stock

Posted by George Bondi on Jun 17th, 2026

TransMedics Group, Inc. (NASDAQ:TMDX – Get Free Report) Director Thomas Gunderson sold 9,624 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $75.06, for a total value of $722,377.44. Following the transaction, the director owned 16,642 shares in the company, valued at approximately $1,249,148.52. This trade represents a 36.64% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

TransMedics Group Price Performance

Shares of NASDAQ:TMDX traded down $2.60 during trading on Wednesday, reaching $73.22. 862,461 shares of the company traded hands, compared to its average volume of 1,090,523. The company’s 50 day moving average is $85.20 and its two-hundred day moving average is $114.02. The firm has a market capitalization of $2.53 billion, a PE ratio of 16.64 and a beta of 1.91. The company has a quick ratio of 6.19, a current ratio of 6.74 and a debt-to-equity ratio of 1.70. TransMedics Group, Inc. has a 52 week low of $60.10 and a 52 week high of $156.00.

TransMedics Group (NASDAQ:TMDX – Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $0.30 EPS for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.32). The company had revenue of $173.93 million during the quarter, compared to the consensus estimate of $174.44 million. TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The firm’s revenue for the quarter was up 21.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.70 EPS. As a group, sell-side analysts predict that TransMedics Group, Inc. will post 1.98 earnings per share for the current year.

Hedge Funds Weigh In On TransMedics Group

A number of institutional investors have recently added to or reduced their stakes in the stock. D.A. Davidson & CO. lifted its stake in TransMedics Group by 0.5% in the 4th quarter. D.A. Davidson & CO. now owns 15,334 shares of the company’s stock valued at $1,865,000 after purchasing an additional 83 shares during the last quarter. Parallel Advisors LLC grew its stake in shares of TransMedics Group by 42.1% during the fourth quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock worth $34,000 after buying an additional 83 shares during the last quarter. HighPoint Advisor Group LLC increased its holdings in shares of TransMedics Group by 3.1% during the fourth quarter. HighPoint Advisor Group LLC now owns 2,955 shares of the company’s stock worth $359,000 after buying an additional 88 shares in the last quarter. Crossmark Global Holdings Inc. lifted its stake in shares of TransMedics Group by 4.0% in the 4th quarter. Crossmark Global Holdings Inc. now owns 2,275 shares of the company’s stock valued at $277,000 after acquiring an additional 88 shares during the last quarter. Finally, Canada Pension Plan Investment Board lifted its stake in shares of TransMedics Group by 2.9% in the 2nd quarter. Canada Pension Plan Investment Board now owns 3,600 shares of the company’s stock valued at $482,000 after acquiring an additional 100 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Canaccord Genuity Group dropped their target price on shares of TransMedics Group from $152.00 to $124.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. TD Cowen decreased their price objective on shares of TransMedics Group from $190.00 to $120.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th. Weiss Ratings restated a “hold (c)” rating on shares of TransMedics Group in a research report on Tuesday, June 9th. Wall Street Zen downgraded TransMedics Group from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, Needham & Company LLC decreased their price target on TransMedics Group from $174.00 to $142.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th. Six analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $134.00.

View Our Latest Research Report on TMDX

About TransMedics Group

(Get Free Report)

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.